{"filings":[{"id":722158,"accession_number":"0001380106-26-000085","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-05-28T20:14:49+00:00","items":["5.07"],"status":"ready","headline":"Rapid Micro Biosystems stockholders elect Richard Kollender as Class II director, ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Richard Kollender re-elected as Class II Director with 23,180,585 votes for, 1,998,525 withheld, 11,920,445 broker non-votes.","Shareholders ratified PricewaterhouseCoopers LLP as independent auditor for FY2026: 37,096,030 for, 3,292 against, 233 abstaining.","Both proposals passed; no other matters were voted on at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":529157,"accession_number":"0001104659-26-063936","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-05-19T21:13:50+00:00","items":["1.01","9.01"],"status":"ready","headline":"RPID raises ~$9M in underwritten common stock and warrant offering; insiders add $140K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 3.58M units (share + two warrants) at $1.955/unit; net proceeds ~$8.9M.","Concurrent direct offering to directors/officers of 71,607 shares plus warrants for gross proceeds ~$140K.","Series A warrants: exercise price $1.955, exercisable after 6 months, 1-year term; Series B: $2.34, 5-year term.","Pre-funded warrants: $1.945 purchase price, $0.01 exercise, immediately exercisable until fully exercised.","Proceeds to fund working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69162,"accession_number":"0001380106-26-000067","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-05-13T20:33:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q1 revenue up 11% to $8.0M; net loss widens to $14.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.0M (+11% YoY); product revenue $5.6M (+36%).","Net loss $14.3M ($0.31/sh) vs $11.3M ($0.26/sh) in Q1 2025.","Recurring revenue $5.1M (+28%), 63% of total; placed 6 Growth Direct systems (3 in Q1 2025).","Gross margin 4.6% vs 5.6% last year; cash and equivalents $23M.","Reaffirms FY2026 guidance: revenue $37-41M, 30-38 system placements, ~20% gross margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103422,"accession_number":"0001380106-26-000045","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"COO John Wilson departs April 10; CEO Spignesi assumes operating role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Wilson, COO, will leave as of April 10, 2026 for family reasons; no disagreement with the Company.","CEO Robert Spignesi will also serve as principal operating officer effective April 10, 2026.","Separation agreement includes consulting at $200/hr, max 20 hrs/month through June 30, 2026.","Vested stock option exercise period extended to March 31, 2027, with weekly sale cap of 20,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103421,"accession_number":"0001380106-26-000029","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Rapid Micro reports record Q4 revenue $11.3M (+37% YoY); 2026 guidance $37-41M; Samsung Biologics expands Growth Direct","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $11.3M (+37% YoY); product revenue $9.3M (+78%).","FY 2025 revenue $33.6M (+20% YoY); net loss $47.1M ($1.05/share).","FY 2026 guidance: revenue $37-41M, 30-38 system placements, gross margin ~20%.","Samsung Biologics placed multi-system Growth Direct order in Q1 2026, following Amgen's Q4 2025 multi-system order.","Cash position $39M; $25M unused under Trinity Capital debt facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103420,"accession_number":"0001380106-26-000007","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems pre-announces record Q4 rev $11.3M (+37% YoY); FY rev $33.6M (+20%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue expected ~$11.3M, up ~37% YoY; record multi-system order from Top 20 biopharma customer.","Full year 2025 revenue expected ~$33.6M, up ~20% YoY; recurring revenue $17.8M (+15%).","Q4 placed 16 new Growth Direct systems, validated 3 customer systems; full year placed 28 and validated 18.","Cumulative installed base: 190 systems globally, 155 validated.","Company to announce complete FY2025 results and 2026 outlook later in Q1 2026."],"consensus_eps_estimate":-0.227,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":33587000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119663,"accession_number":"0001380106-25-000195","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q3 revenue $7.8M (+3% YoY); raises FY guidance after record multi-system order","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $7.8M (+3% YoY); recurring revenue up 32% to $4.8M on record consumables.","Net loss $11.5M ($0.26 loss per share), flat YoY; gross margin improved to 9% from 8%.","Receives largest multi-system order in company history from existing Top 20 global biopharma customer.","Raises FY2025 revenue guidance to at least $33.0M, assumes at least 27 Growth Direct placements.","Cash and equivalents $42M as of Sept 30, 2025."],"consensus_eps_estimate":-0.2499,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":22305000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136238,"accession_number":"0001380106-25-000169","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q2 revenue $7.3M (+10% YoY); enters $45M term loan with Trinity Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Q2 2025 revenue $7.3M, up 10% YoY; net loss $11.9M ($0.27/sh) vs $12.6M ($0.29) prior year.","Gross margin turned positive at 4% (vs -3% in Q2 2024); recurring revenue up 15% to $4.4M.","Reaffirms FY2025 revenue guidance of at least $32.0M.","Entered $45M term loan facility with Trinity Capital; $20M drawn at close, no financial covenants.","Initial interest rate 11.5% p.a.; 36-month interest-only period; warrants for 179,104 shares at $3.35/sh."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153311,"accession_number":"0001380106-25-000153","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEO Robert Spignesi diagnosed with treatable lymphoma; will continue to lead company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Robert Spignesi disclosed a recent diagnosis of a treatable form of lymphoma.","Treatment expected to last approximately four months; doctors gave a good prognosis.","Spignesi will continue to actively lead the business with limited in-person time and travel.","Board and leadership team are fully supportive of his continued role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153310,"accession_number":"0001380106-25-000114","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Director Jeffrey Schwartz resigns from Rapid Micro Biosystems board effective May 22, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Schwartz resigned as director and chair of nominating and corporate governance committee; not due to any disagreement.","Annual meeting elected Dafni Bika, Ph.D. and Inese Lowenstein as Class I directors for terms expiring 2028.","Stockholders ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year ending Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153309,"accession_number":"0001380106-25-000099","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Q1 revenue $7.2M (+28% YoY), gross margin turns positive 6%, net loss narrows to $11.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $4.1M (+10%), service revenue $3.1M (+64%) driven by record validation activity; 3 new Growth Direct placements.","Gross margin improved to 6% from -27% in Q1 2024; total operating expenses down 5% to $12.1M.","Net loss per share $0.26 vs $0.31; cash & equivalents $42M with no debt outstanding.","Global distribution agreement with MilliporeSigma (Merck KGaA) announced; joint training and planning underway.","FY2025 guidance reaffirmed: total revenue at least $32M with 21-25 system placements."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":7205000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172104,"accession_number":"0001380106-25-000066","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems updates corporate presentation for investor meetings","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a corporate presentation dated March 4, 2025, via 8-K under Item 7.01.","Presentation is intended for use with investors, analysts, and at the TD Cowen Health Care Conference.","No specific financial results, guidance, or material operational updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172103,"accession_number":"0001380106-25-000050","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q4 revenue $8.2M (+30% YoY); gross margin turns positive; announces MilliporeSigma deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $8.2M (up 30% vs $6.3M in Q4 2023); product revenue $5.2M (+27%), service revenue $3.0M (+35%).","Q4 gross margin 12% (improved from negative 3% in Q4 2023); net loss $9.7M ($0.22 loss per share) vs $11.2M loss.","FY 2024 revenue $28.1M (+25%); net loss $46.9M ($1.08 per share) improved from $52.5M loss in 2023.","FY 2025 guidance: total revenue at least $32.0M with 21-25 system placements expected.","Entered global Distribution & Collaboration Agreement with MilliporeSigma for co-exclusive rights to sell Growth Direct systems and consumables."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":28051000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172102,"accession_number":"0001380106-25-000043","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems signs global distribution deal with Merck KGaA's MilliporeSigma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MilliporeSigma gets co-exclusive global rights to sell Growth Direct systems and consumables in pharma, med device, personal care, cosmetics, food & beverage.","MilliporeSigma commits to minimum Growth Direct system purchases in first two years; initial term is five years.","Parties intend to negotiate supply agreement within 6 months and services agreement within 1 year to improve gross margins.","Rapid Micro retains responsibility for installation, validation, and service; existing direct sales and distribution channels continue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172101,"accession_number":"0001380106-25-000015","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems posts updated corporate presentation; no material financial updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated corporate presentation on January 16, 2025 for use with investors.","Presentation contains no new financial results, guidance changes, or business developments.","No earnings, M&A, or other material events disclosed in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172100,"accession_number":"0001380106-25-000009","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro prelim Q4 rev record $8.2M, +30% YoY; Lonza collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue preliminary ~$8.2M (record), +30% YoY; recurring rev ~$4.2M, +27% YoY.","FY 2024 total rev ~$28.1M, +25% YoY; recurring rev ~$15.5M, +14% YoY.","Placed 6 new Growth Direct systems in Q4; 21 systems placed in FY 2024; cumulative >160 placed globally.","Collaborated with Lonza to integrate Growth Direct with MODA-EM; Lonza deploying across global cell and gene therapy network.","Preliminary results unaudited; final results and 2025 outlook expected later in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":28051000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189074,"accession_number":"0001380106-24-000202","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter on Nov 11, 2024 confirming compliance with $1.00 minimum bid price rule.","Compliance met after closing bid price >= $1.00 for 10 consecutive business days.","Earlier had until Jan 27, 2025 to cure; transferred to Nasdaq Capital Market on Aug 5, 2024.","Delisting risk now removed; listing continues on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189073,"accession_number":"0001380106-24-000191","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"RPID Q3 rev $7.6M (+24%), gross margin turns positive; director resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.6M (+24% YoY); seven Growth Direct placements; gross margin positive 8% vs -27% last year.","Net loss $11.3M ($0.26/sh) vs $13.4M ($0.31) prior year.","Reaffirms FY2024 revenue guidance ≥$27.0M and ≥20 system placements.","David Hirsch resigns from board effective Nov 1; not due to disagreement, served since 2013."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":19833000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205556,"accession_number":"0001380106-24-000162","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q2 revenue up 32% to $6.6M; Nasdaq transfer due to bid price deficiency","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $6.6M (+32% YoY); net loss $12.6M ($0.29 loss per share) vs $14.0M loss a year ago.","Gross margin improved 35pp vs Q2 2023; five Growth Direct systems placed; 150th system with top 15 pharma.","Operational efficiency program: ~$7M annual savings; workforce reduction; aiming for positive cash flow by end-2027.","Stock to transfer from Nasdaq Global Select to Nasdaq Capital Market on Aug 5 due to bid price <$1; 180-day compliance period.","Reaffirms FY2024 revenue guidance >=$27M (>=20% growth) and at least 20 system placements."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":12229000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222495,"accession_number":"0001380106-24-000132","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"RPID shareholders approve officer exculpation charter amendment, elect three directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Certificate of Amendment to allow officer exculpation under Delaware law; effective May 23, 2024.","Directors elected: Kirk D. Malloy (26.1M for), Melinda Litherland (25.7M for), Robert Spignesi (25.7M for).","Ratified PricewaterhouseCoopers as independent auditor for FY2024: 34.2M for, 0.79M against.","37.5M shares of Class A common eligible; 35.0M shares present at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222494,"accession_number":"0001380106-24-000125","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q1 revenue $5.6M (+11% YoY), loss $13.3M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $5.6M (+11% YoY); net loss $13.3M ($0.31/share).","Recurring revenue $3.7M (+15% YoY); record consumable revenue.","Placed three Growth Direct systems; reaffirms FY2024 revenue guidance of at least $27M.","Cash, equivalents and investments $79.5M; no debt; runway into H2 2026.","Growth Direct Rapid Sterility platform on track for mid-2024 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":5611000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242016,"accession_number":"0001380106-24-000058","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q4 revenue $6.3M (+45% YoY); guides FY2024 revenue ≥$27M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $6.3M (+45% YoY); placed 6 Growth Direct systems, highest since Q3 2021.","FY2023 revenue $22.5M (+31% YoY); net loss $52.5M vs $60.8M in 2022, loss narrowed.","Gross margin improved to near breakeven (-3%) from -59% in Q4 2022 on cost actions.","Cash $95M, no debt; expected runway into H2 2026.","FY2024 guidance: revenue ≥$27M, at least 20 system placements; new Rapid Sterility app by mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242015,"accession_number":"0001380106-24-000014","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Rapid Micro Biosystems receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified RPID on Feb 2, 2024, that bid price closed below $1.00 for 30 consecutive business days (Dec 18, 2023 - Feb 1, 2024).","Company has 180 calendar days, until July 31, 2024, to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not cured by July 31, RPID may transfer to Nasdaq Capital Market for an additional 180-day compliance period.","Failure to regain compliance could result in delisting from Nasdaq; no immediate effect on listing.","RPID intends to monitor bid price and take measures to regain compliance, but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242014,"accession_number":"0001380106-24-000009","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Rapid Micro Q4 rev ~$6.2-6.4M (+45%); FY rev ~$22.4-22.6M (+30%); cash $95M runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue expected $6.2-6.4M (+45% YoY); FY23 revenue $22.4-22.6M (+30% YoY).","Placed 16 Growth Direct systems in FY23, 6 in Q4; 18 validations completed in FY23.","Cash and investments ~$95M as of Dec 31, 2023; cash runway at least into H2 2026.","Growth Direct selected by Samsung Biologics; systems now placed with 100% of commercial CAR-T manufacturers.","Commercial launch of Growth Direct Rapid Sterility app expected by mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":22519000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259412,"accession_number":"0001380106-23-000173","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q3 revenue $6.1M (+30% YoY); reaffirms FY23 guidance at least $22M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $6.1M, up 30% YoY; placed 5 Growth Direct systems, validated 4.","Net loss $13.4M ($0.31 EPS) vs $16.3M ($0.38) in Q3 2022; loss narrowed.","Recurring revenue $3.4M (+17%); cash $104M, no debt, runway into 2026.","Reaffirms FY23 revenue at least $22M (~30% growth) and at least 15 system placements.","Added a new top 5 global pharma customer; now serves two-thirds of top 20."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":16182000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276688,"accession_number":"0001380106-23-000165","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rapid Micro Biosystems regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency notice on Sept 13 after bid price below $1 for 30 consecutive days (July 31-Sept 11).","Given 180-day cure period until March 11, 2024 to regain compliance.","Regained compliance after 10 consecutive business days (Sept 12-25) with closing bid price at or above $1.","Nasdaq closed the matter on Sept 26, 2023; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276687,"accession_number":"0001380106-23-000161","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Rapid Micro Biosystems receives Nasdaq delisting notice over bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Sept 13, 2023; bid price below $1.00 for 30 consecutive business days ending Sept 11, 2023.","180-day compliance period expires March 11, 2024; must close at $1.00+ for 10 consecutive days.","Since Sept 12, bid price has been above $1.00 for six consecutive business days through Sept 19.","If not compliant by March 2024, may transfer to Nasdaq Capital Market for another 180-day cure period.","No immediate delisting; company monitors and will take reasonable measures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276686,"accession_number":"0001380106-23-000142","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q2 revenue $5.0M (+30% YoY); net loss $14.0M; reaffirms FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $5.0M, up 30% from $3.9M in Q2 2022; net loss $14.0M ($0.33 per share) vs $13.1M ($0.31).","Recurring revenue $3.6M, up 44% YoY; record consumable revenue; placed two new Growth Direct systems.","Cash, cash equivalents and investments $113.3M as of June 30, 2023; no debt; cash runway into 2026.","Reaffirmed FY2023 revenue guidance of at least $22.0M (~30% growth) and at least 15 system placements.","Appointed Kirk Malloy, Ph.D. as Chair of the Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":10037000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276685,"accession_number":"0001380106-23-000130","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems appoints Kirk Malloy as Chair of Board, expands board to eight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kirk Malloy appointed as Class III director and Chair of Board, effective July 14, 2023.","Jeffrey Schwartz steps down as Chair but remains director; David Hirsch resigns as Compensation Committee Chair.","Malloy receives options for 50,000 shares at $0.9702, plus annual cash comp: $40k director, $45k Chair, $15k Comp Comm Chair.","Malloy has 25+ years life sciences experience at Illumina, Qiagen, Verogen; serves on boards of NanoString and DermTech.","Board expands from seven to eight members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294475,"accession_number":"0001380106-23-000093","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Rapid Micro Biosystems stockholders elect Schwartz, Kollender, Ricciardi as Class II directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey Schwartz received 26,007,817 votes for and 1,756,781 withheld; broker non-votes 7,071,880.","Richard Kollender received 23,893,108 for and 3,871,490 withheld; broker non-votes 7,071,880.","Natale Ricciardi received 25,721,530 for and 2,043,068 withheld; broker non-votes 7,071,880.","Ratification of PricewaterhouseCoopers as auditor passed with 34,810,913 for, 24,946 against, 619 abstain.","Annual meeting held May 4, 2023; 34,836,478 shares present out of 36,635,108 eligible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294474,"accession_number":"0001380106-23-000072","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q1 revenue $5.0M (+21% YoY); reaffirms FY23 guidance of at least $22.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $5.0M, up 21% YoY; recurring revenue $3.3M (+22%).","Net loss $13.9M ($0.32/share) vs $14.9M ($0.35) in Q1 2022.","Placed three Growth Direct systems; two systems validated in the quarter.","Reaffirmed FY2023 revenue guidance of at least $22.0M (~30% growth) and at least 15 placements.","Appointed Michael Wysocki SVP Sales and Marketing; cash $122.1M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":5035000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315071,"accession_number":"0001380106-23-000011","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q4 commercial revenue $4.4M, FY2022 $17.1M; guides FY2023 at least $22M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 commercial revenue $4.4M (vs $4.9M prior year); net loss $16.4M ($0.39 per share).","Full year 2022 commercial revenue $17.1M (vs $21.6M prior year); net loss $60.8M ($1.43 per share).","Recurring commercial revenue grew 28% in Q4 to $2.9M; full year recurring revenue $11.0M (+40% YoY).","Placed 2 new systems in Q4, 9 in full year; cumulative 125 placed, 103 validated systems.","FY2023 guidance: commercial revenue at least $22M, with at least 15 new system placements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315070,"accession_number":"0001380106-23-000004","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems prelim FY2022 revenue $17.0-17.2M; Q4 $4.2-4.4M; cash $140M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 commercial revenue expected $17.0-17.2M; Q4 revenue $4.2-4.4M, in line with expectations.","Placed 9 new Growth Direct systems and completed validation of 19 systems in FY2022.","Ended 2022 with ~$140M cash and investments, providing runway at least into 2026.","Added new global Top 20 pharma customer in U.S. and large pharma customer in Japan.","Launched RMBNucleus Mold Alarm software; to present at J.P. Morgan Healthcare Conference Jan 12."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":17133000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333412,"accession_number":"0001380106-22-000054","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems ends strategic review; no binding offers received for sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board concludes review of strategic alternatives that began August 2022; no parties submitted binding offers to acquire all outstanding shares.","Company to continue executing current strategy: enhance commercial execution, product development, expand Growth Direct market.","As of Q3 2022, cash, cash equivalents and investments total $150.1M with no debt; cash runway expected into 2026.","CEO cites recent actions to right-size cost structure and manage cash to secure long runway.","Board confident in management's strategy to drive improved performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333411,"accession_number":"0001380106-22-000044","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q3 commercial revenue $4.7M, net loss $16.3M, reaffirms FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $4.7M (down 25% YoY from $6.3M); recurring revenue up 34% to $2.9M.","Placed 3 Growth Direct systems in Q3 vs 10 in prior year; validated 4 customer systems.","Net loss $16.3M ($0.38/share) vs $25.0M ($0.71) in Q3 2021; ops expenses rose on strategic review and restructuring.","Reaffirms FY2022 revenue at least $17M; expects at least 2 system placements in Q4.","Cash $150.1M, no debt; strategic review ongoing; restructuring plan targets $8-9M annual savings by Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":12759000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350922,"accession_number":"0001558370-22-013401","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["1.01","2.02","2.05","3.03","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q2 revenue $3.9M; lowers FY22 outlook to ≥$17M, cuts 20% workforce","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 commercial revenue $3.9M vs $5.7M YoY; net loss $13.1M ($0.31 loss per share).","Full-year 2022 revenue guidance reduced to at least $17.0M (from prior higher outlook); expects 3-5 system placements in H2.","Implements restructuring: 20% workforce reduction, $1.5M charge in Q3, expected $8-9M annualized cost savings.","CCO Andy Keys departs; CEO Robert Spignesi assumes commercial leadership.","Board launches strategic alternatives review; rejects Kennedy Lewis $5.00/share acquisition proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":8020000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368129,"accession_number":"0001380106-22-000034","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rapid Micro Biosystems elects two Class I directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Hirsch (26.8M for, 4.1M withheld) and Inese Lowenstein (31.0M for, 16k withheld) elected to board until 2025.","Stockholders ratified PricewaterhouseCoopers as independent auditor for FY2022 with 33,021,093 for, 99 against.","Broker non-votes on director election totaled 2,051,666 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368128,"accession_number":"0001380106-22-000026","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q1 commercial revenue $4.2M, down from $4.8M; reaffirms FY2022 revenue $27-32M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $4.2M (Q1 2021: $4.8M, including $0.2M BARDA); recurring revenue up 66% to $2.7M.","Net loss ($14.9M) vs ($22.1M) prior year; EPS ($0.35) reflecting higher share count after IPO.","Cash and investments $184.2M, no debt; reaffirms FY2022 revenue guidance $27-32M (growth 25-50%).","Placed 2 systems, completed validation of 9 systems; expects Q2 system placements similar to Q1.","Beta testing of rapid sterility system with global top 20 pharma expected to begin later in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":4160000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387458,"accession_number":"0001380106-22-000015","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Alexander Schmitz to not stand for reelection at 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alexander Schmitz, independent Class I director, will not seek reelection at the 2022 Annual Meeting.","He serves on Audit and Compensation Committees and will remain until the Annual Meeting.","Decision not due to any disagreement with Rapid Micro Biosystems.","No replacement director announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387457,"accession_number":"0001380106-22-000007","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems FY2021 commercial revenue up 54% to $21.6M; net loss $73.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 total revenue $23.2M vs $16.1M; commercial revenue $21.6M (+54%); net loss $73.5M vs $37.1M.","Q4 2021 total revenue $5.2M flat YoY; commercial revenue $4.9M; recurring revenue $2.3M (+91%).","FY2022 commercial revenue guidance reaffirmed at $27M-$32M (25-50% growth).","Cash, cash equivalents and investments $203.5M, no debt.","Placed 29 new systems FY2021; cumulative placed 116, validated 84."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387456,"accession_number":"0001380106-22-000003","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Bio pre-announces Q4 rev $4.7-5.2M; FY22 outlook $27-32M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 total revenue $4.7M-$5.2M; commercial $4.5M-$4.9M; non-commercial (BARDA) $0.2M-$0.3M.","Full year 2021 total revenue $22.8M-$23.3M; commercial $21.3M-$21.7M; placed 29 systems, validated 33.","Recurring revenue grew ~90% in Q4 vs prior-year period; 16 systems validated in Q4.","FY2022 commercial revenue outlook $27M-$32M, 25%-50% growth over preliminary FY2021 commercial revenue.","Ended 2021 with >$200M cash and investments, zero debt; COVID headwinds impacted Q4 placements."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":23232000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405390,"accession_number":"0001380106-21-000019","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2021-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems appoints Inese Lowenstein to Board of Directors; 25,000 options granted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lowenstein appointed as Class III director effective Dec 17, 2021; term expires at 2024 annual meeting.","She joins Audit Committee; board determined independence under Nasdaq and Exchange Act standards.","Received option to purchase 25,000 shares of Class A common stock at $11.23, vesting over 36 months.","Currently serves as Senior Talent Advisor at Danaher; previously President of SCIEX at Danaher.","No arrangements or transactions disclosed; standard non-employee director compensation applied."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405389,"accession_number":"0001380106-21-000008","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q3 commercial revenue $6.3M (+27%); reaffirms FY21 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Commercial revenue $6.3M (+27% YoY); recurring commercial revenue $2.2M (+154% YoY).","Net loss of $25.0M includes $8.2M warrant fair-value adjustment and $3.1M debt-repayment charge.","Cash $220M, no debt; repaid $28.7M term debt in September using IPO proceeds.","Placed 10 Growth Direct systems and completed validation of 5 customer systems in Q3.","Reaffirms FY2021 commercial revenue outlook of at least $24M, representing ≥70% YoY growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":18024000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424442,"accession_number":"0001558370-21-012702","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2021-09-23T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems pays $28.7M to terminate Kennedy Lewis loan, releases liens","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Paid $28.7M to terminate Loan and Security Agreement with Kennedy Lewis Management LP.","Outstanding obligations included $26.2M principal, $1.83M prepayment premium, $0.68M interest/fees.","All liens on company assets released; securities and warrants survive.","Loan originally $25M principal (May 2020) plus $1.2M accrued paid-in-kind interest.","Termination effective September 17, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424441,"accession_number":"0001104659-21-109803","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2021-08-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Q2 commercial revenue $5.7M (+135% YoY); full-year outlook at least $24M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $6.1M vs $2.6M YoY; net loss ($11.8M) vs ($9.3M) YoY.","Placed 8 new systems (cumulative 103); validated 11 systems (cumulative 63).","Sold one-millionth consumable since Growth Direct commercial launch.","Completed IPO in July 2021: ~9M shares sold, $165.3M net proceeds; pro forma cash ~$260M.","Full-year 2021 commercial revenue guidance: at least $24.0M (≥70% YoY growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":-57.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":11125000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424440,"accession_number":"0001104659-21-094046","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2021-07-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Rapid Micro Biosystems files restated certificate and bylaws effective with IPO closing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed restated certificate with Delaware on July 19, 2021, effective upon IPO closing.","Authorized capital: 210M Class A common, 10M Class B common, and 10M undesignated preferred shares.","Established classified board with staggered three-year terms; directors removable only for cause with two-thirds vote.","Eliminated stockholder action by written consent; designated Delaware and federal courts as exclusive forums.","Board and stockholders approved the documents prior to effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90279253.68,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}